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Available online 25 July 2004AbstractTranscription of the immediate early gene BZLF1 is mediated initially through the activation of cellular transcription factors. Reporter-
based studies have provided evidence that following this initial activation, the BZLF1 gene product Zta may be involved in an autoactivation
loop through binding to its promoter Zp. In contrast, other reports have shown that transfection of a Zta expression vector in latently infected
cells does not activate endogenous Zp. Using chromatin immunoprecipitation (ChIP) assays, we show here that Zta binds to endogenous Zp
following induction of the lytic cycle by anti-Ig and TGF-beta1 and that binding occurs early enough to play a role in the activation of Zp. We
have also generated a dominant-negative Zta and shown that it inhibits activation of endogenous Zp. These data support a two-step model for
Zp activation during reactivation involving initial activation by cellular factors followed by an autoactivation step.
D 2004 Elsevier Inc. All rights reserved.
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Following initial exposure, the Epstein–Barr virus (EBV)
establishes a persistent infection and exists in a predom-
inantly latent state for the life of the host (Kieff and
Liebowitz, 1990; Miller, 1990). Despite this predominantly
latent state, EBV intermittently reactivates leading to the
production of infectious virions. Although the triggers that
elicit the switch from latency to lytic replication cycle in
vivo are largely unknown, it is possible that changes in local
cytokine environment or engagement of antigen may induce
reactivation in a fraction of EBV-positive B lymphocytes. In
tissue culture, these mechanisms can be modeled by treating
EBV-positive B cell lines with TGF-beta1 or through cross-0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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E-mail address: eflemin@tulane.edu (E.K. Flemington).linking the immunoglobulin receptor with an anti-immuno-
globulin antibody, respectively.
A key regulator mediating the transition from the latent
to the lytic phase is the viral transactivator Zta (also called
ZEBRA, BZLF1, and EB1; Countryman et al., 1987; Miller
et al., 1984). Zta, along with the viral transactivator Rta, is
the first viral gene expressed after stimulation of the lytic
cycle (Takada and Ono, 1989). Further, transfection of an
expression vector containing the Zta reading frame leads to
induction of the entire lytic cascade resulting in viral
production (Countryman et al., 1987; Miller et al., 1984).
Therefore, control of the Zta promoter Zp is a key regulatory
point in the transition from latency to the lytic replication
cycle.
A number of functional regulatory elements in Zp have
been identified by DNase I footprint analysis (Flemington
and Speck, 1990a,b) and transcription factors that bind these
elements have been determined (Adamson et al., 2000;
Borras et al., 1996; Kraus et al., 2001, 2003; Liu et al.,04) 134–143
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(Fig. 1). Interestingly, several elements have been shown to
inhibit Zp activity in the absence of inducing signals
including ZV (Kraus et al., 2001, 2003), ZIIR (Liu et al.,
1998), and the MEF2D binding sites (Borras et al., 1996;
Flemington and Speck, 1990b; Gruffat et al., 2002).
MEF2D has also been shown to recruit histone deacetylases
to Zp that presumably compacts the chromatin structure
(Gruffat et al., 2002). The standard model for Zp activation
includes an initial reversal of the inhibitory effects of the
negative promoter elements (perhaps in part through
dissociation of HDACs) followed by the recruitment of
activating factors such as histone acetylases by transcription
factors bound to Zp. These changes would result in an
opening of the local chromatin structure and remodeling in a
way that allows transcription initiation to ensue.
Footprinting studies identified two Zta binding sites in
Zp (Flemington and Speck, 1990a; Lieberman and Berk,
1990) and co-transfection of Zta expression vectors with Zp
reporter plasmids showed that Zta can bind these two
elements and activate Zp transcription (Flemington and
Speck, 1990a; Urier et al., 1989). This suggested that
following the initial induction of Zp by cellular factors,
newly synthesized Zta could then bind Zp and support high
level expression of Zta (Flemington and Speck, 1990a).
Importantly, however, subsequent studies reported that
transfection of a Zta expression vector into EBV-positive
cells did not result in induction of the endogenous Zta
promoter (Kolman et al., 1996; Le Roux et al., 1996). The
ability of Zta to activate a Zp reporter construct that is added
to cells in a naked form (i.e., without associated chromatin
proteins) but not endogenous Zp, which is presumably
maintained in a compact chromatin structure, suggested that
binding of Zta to Zp may be regulated in part through
accessibility issues. Alternatively, Zta may bind Zp but may
not have the capacity to overcome imprinted inhibitory
signals at Zp. We therefore tested whether Zta binds
endogenous Zp during the activation stages of Zp following
treatment of EBV-positive cells with lytic cycle-inducing
agents. In addition, using a dominant-negative Zta, we
tested whether Zta function is required for full Zp activity
under these inducing conditions.Fig. 1. Schematic representation of Zp. The homologous ZI elements (ZIA, ZIB,
domain has been shown to bind members of the ATF/CREB family. The transcr
repressor factor has been implicated in binding adjacent to the CREB/ATF bindinResults
Binding of Zta to Zp following anti-Ig treatment of Akata
cells
Chromatin immunoprecipitation (ChIP) analysis was
used to assess the binding of Zta to Zp during reactivation.
Akata cells were treated for 0, 2, or 4 h with 1 Ag/ml anti-Ig,
and the cells were cross-linked with formaldehyde. Cell
lysates were generated, the genomic DNAwas sheared to an
average size of approximately 500 bp, and the samples were
subjected to immunoprecipitation with either a control or an
anti-Zta antibody (Taylor et al., 1989). The amount of Zp
precipitated was determined using real-time PCR with the
primers Zpleft and Zpright that give rise to a 181-bp product
extending from 191 to 11 of Zp (Fig. 1). A correlation
coefficient of 0.997 and a PCR efficiency of 100% were
observed for the standard curve indicating a high degree of
accuracy (Fig. 2). The melting temperature profiles indicate
the presence of only one product for all PCR reactions (Fig.
2), and this was verified by agarose electrophoresis (data not
shown). As shown in Fig. 2, the amount of Zp precipitated
by a Zta antibody in Akata cells not treated with anti-Ig was
similar to the amount of Zp precipitated with a control
antibody. In contrast, a significant increase in the amount of
Zp was precipitated with a Zta antibody in cells treated for 2
or 4 h with anti-IgG.
To determine whether this increase is specific to Zp,
ChIP analysis was carried out again and the immunopreci-
pitated material was used for PCR reactions with Zp primers
as well as primers for the latency promoter Qp. As shown in
Fig. 3, although an increase in the amount of Zp precipitated
with the Zta antibody is observed at 2, 4, and 8 h post-
induction, there is little change in the amount of Qp. To
establish that the DNA-shearing step was sufficient to
prevent the precipitation of Zta bound to distal Zta binding
sites surrounding Zp, the precipitated material was also
subjected to PCR using primers for the third exon of the
BZLF1 gene, which amplifies a fragment that is 857 bp
downstream from the Zp transcription initiation site. No
significant change in the amount of the exon 3 region of
BZLF1 was seen in the Zta precipitate, suggesting that theZIC, and ZID) have been shown to bind either SP1/3 or MEF2D. The ZII
iption factor ZEB has been shown to bind the ZV element and a putative
g sequences. PCR primers used for Zp ChIP experiments are indicated.
Fig. 2. Chromatin immunoprecipitation (ChIP) analysis of Zta binding to Zp following treatment with anti-Ig. Akata cells were treated with anti-Ig for 0, 2, or 4 h and cell lysates were subjected to
immunoprecipitation with either no antibody or an anti-Zta antibody (a gift from George Miller, Yale). Real-time PCR was then carried out to quantitate the amounts of co-precipitating Zta promoter (Zp). For bar
































Fig. 3. Binding of Zta to Zp following induction of the lytic cycle with anti-
Ig. Akata cells were treated with anti-Ig for 0, 2, 4, or 8 h and cell lysates
were subjected to immunoprecipitation with either a control or an anti-Zta
antibody. Real-time PCR was then carried out to quantitate the amounts of
the Zta promoter (Zp), the group I latency promoter (Qp), or the third exon
of the BZLF1 gene (Exon 3). Data are plotted against control antibody at 0
h. Standard deviation was used to calculate error.
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antibody is likely to represent binding of Zta to bona fide
promoter sequences.
Binding of Zta to Zp in TGF-beta1-treated Mutu I cells
To test whether Zta binds Zp following cytokine-induced
reactivation, ChIP analysis was carried out following
treatment of Mutu I cells with TGF-beta1. Mutu I cells
were cultured for 0, 4, 8, or 24 h in the presence of 5 ng/ml
TGF-beta1 and processed as above. A significant increase in
the amount of Zp precipitated with the anti-Zta antibody
was observed at 4, 8, and 24 h post-induction (Fig. 4),
indicating that Zta binds Zp following TGF-beta1-mediated
reactivation in Mutu I cells. In contrast, no significant
increase in Zta binding to Qp or to another latency promoter
LMP1 was seen following induction of the lytic cycle with
TGF-beta1. This supports the idea that the increase in the
binding of Zta to Zp following activation of the lytic cycle
with TGF-beta1 is specific to lytic-related genes.
Generation of a dominant-negative Zta
The data presented above indicate that Zta binds Zp
following either anti-Ig or TGF-beta1 stimulation and that
binding occurs during the activation phase of Zp. The
timing of binding supports the hypothesis that Zta plays a
positive role in Zp function. However, to more directly
address whether Zta is required for full Zp function, we
generated a truncated form of Zta that contains the Zta
homodimerization domain but which should be defective for
transcriptional activation as well as DNA binding with the
idea that this may act as a dominant-negative form of Zta
and inhibit the transcriptional activation function of wild-
type Zta. As shown in Fig. 5A, the entire Zta activation
domain has been deleted and serine 186, which is in the
basic/DNA binding domain of Zta, was mutated to glutamic
acid. Previous studies have shown that this point mutation
abrogates the DNA binding properties of Zta (Baumann et
al., 1998), and we have shown previously that deletion of
the activation domain results in severely impaired activation
function (Flemington et al., 1992). Importantly, although we
have reported that Zta can induce cell growth arrest, we
have also shown that the serine 186 to glutamic acid
mutation largely abrogates Zta’s growth arrest properties
(Rodriguez et al., 2001). In addition, we have also shown
that deletion of the Zta activation domain abrogates Zta’s
ability to induce the expression of the cyclin-dependent
kinase inhibitor p27 (Rodriguez et al., 1999). We were
therefore hopeful that this Zta mutant would be able to
inhibit the function of wild-type Zta but would be defective
for Zta’s cell growth arrest activity.
Co-transfection of the EBV-positive cell line NPC-KT
with wild-type Zta and either a control (pMSCV) or the Zdn
expression vector (pMSCV-Zdn) shows that Zdn inhibits the
ability of Zta to activate expression of the Zta-responsive
Fig. 4. Binding of Zta to Zp following induction of the lytic cycle with
TGF-beta1. Mutu I cells were treated with TGF-beta1 for 0, 4, 8, or 24 h,
and cell lysates were subjected to immunoprecipitation with either a control
or an anti-Zta antibody. Real-time PCR was then carried out to quantitate
the amounts of the Zta promoter (Zp), the group I latency promoter (Qp), or
the promoter for the latency membrane protein LMP1 (LMP1p). Data are
plotted against control antibody at 0 h. Standard deviation was used to
calculate error.
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NPC-KT lines carrying either pMSCV or pMSCV-Zdn and
found that (1) approximately equal numbers of colonieswere observed in both pMSCV- and pMSCV-Zdn-trans-
fected cultures, and (2) that pMSCV-Zdn clones grow at
approximately the same rate as pMSCV colonies (data not
shown). Together, these data support the idea that Zdn can
be used to address whether Zta is required for activation of
Zp during anti-Ig- or TGF-beta1-mediated reactivation.
Inhibition of endogenous Zta expression by Zdn
To address whether Zdn inhibits anti-Ig- or TGF-beta1-
mediated activation of Zp, we utilized Mutu I cells for the
following reasons. First, Mutu I cells are responsive to both
TGF-beta1 and anti-IgM. Second, in our hands, we have
been able to obtain close to 100% infection efficiencies
through retroviral transduction (data not shown). In contrast,
we typically obtain approximately 20–30% transduction
efficiencies in Akata cells. We felt this was important
because we wanted to carry out induction experiments in
cells that had not been subjected to prolonged antibiotic
selection that could select for subcultures of cells with
distinct phenotypes. Mutu I cells were therefore infected
with either pMSCVor pMSCV-Zdn retrovirus and incubated
for 2 days before the addition of puromycin (Fig. 6).
Infected cells were cultured for 5 days in the presence of
puromycin before they were treated with either anti-IgM,
TGF-beta1, or tricostatin A (TSA). During the puromycin
selection process, little cell death was observed in the
infectants whereas uninfected Mutu I cells are completely
nonviable within 3 days of culture in puromycin. In
addition, no difference in growth rate was observed between
pMSCV- and pMSCV-Zdn-infected cells even after pro-
longed culturing (i.e., 3 weeks, data not shown).
As shown in Fig. 6, Zdn inhibits the expression of
BMRF1 in Mutu I cells following either anti-IgM, TGF-
beta1, or TSA treatment indicating the presence of func-
tional Zdn. Analysis of endogenous Zta expression indi-
cated that indeed, Zdn inhibits (but does not completely
block) the function of Zp following either of these
treatments (Fig. 6). Expression of Rta was similarly
inhibited by Zdn, indicating that Zta likely plays a role in
the full activation of the Rta promoter Rp during these
reactivation conditions. Analysis of the phosphorylation
status of the MAP kinase ERK1/2 indicated that signaling is
not grossly impaired in Zdn-infected cells (Fig. 6), suggest-
ing that inhibition of Zp function is indeed due to inhibition
of endogenous Zta function.Discussion
The data presented here show that Zta binds to its own
promoter following reactivation of the lytic cycle with two
inducing agents that may mimic physiological signaling,
anti-Ig, and TGF-beta1. The binding of Zta to Zp using
ChIP analysis following anti-Ig treatment of Akata cells has
recently been reported (Wu et al., 2004). However, this
Fig. 5. (A) Schematic representation of Zta structure and the sequence of the Zdn. (B) Analysis of Zdn function in NPC-KTcells. Cells were transfected with 1 Ag
of BS(SVp/e)-Zta [or the control, BS(SVp/e)] or 2 Ag of pMSCV-puro-Zdn (or the control, pMSCV-puro) and analyzed for expression of the indicated proteins
by Western blot analysis using antibodies against Zta (Argene, Cat# 11-007), BMRF1 (Capricorn, EBV12900), and Actin (Sigma, Cat#A4700).
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past the point of maximal Zta expression in Akata cells,
which occurs at approximately 4–6 h post-induction
(Flemington et al., 1991; Takada and Ono, 1989). Our
studies show that binding of Zta to Zp occurs specifically
during the activation stages of Zp, therefore demonstrating
that the binding of Zta to Zp is temporally consistent with
Zta playing a positive role in the activation of Zp during
anti-Ig- and TGF-beta1-induced reactivation. In addition,
we have generated a dominant-negative form of Zta (Zdn)
and have shown that Zdn inhibits induction of Zta. Together,
these data strongly support a role for Zta in regulating its
own promoter during reactivation.
It is notable that in Zdn-infected cells, there is still some
degree of activation of endogenous Zta expression. This isFig. 6. Analysis of Zta expression in MutuI cells infected with either pMSCV-pu
methods and selected for 5 days in the presence of puromycin. Cultures were then
analysis using antibodies against Zta (Argene, Cat# 11-007), BMRF1 (Capricorn
phosphorylated ERK1/2 (Cell Signaling, Cat#9106).consistent with the idea that cellular factors play an initial
role in activation of Zp. Nevertheless, it is also reasonable to
assume that Zdn is not 100% effective in inhibition of
endogenous Zta function. Therefore, based on our current
data, we cannot make conclusions as to the relative
contribution of autoactivation vs. initial induction by
cellular factors. But it is clear that Zdn significantly inhibits
Zp function and therefore our data support the two-step
model for activation involving initial activation through
cellular transcription factors followed by a commitment step
that is enforced by an autoactivation mechanism.
How can our data be reconciled with previous studies
showing that ectopic expression of Zta in EBV-positive cell
lines does not induce endogenous Zp? It is possible that
during latency, Zp exists in a compacted chromatinro or pMSCV-puro-Zdn. Cells were infected as described in Materials and
induced as described in Materials and methods and assayed by Western blot
, EBV12900), and Actin (Sigma, Cat#A4700), Rta (Argene, 11-008), and
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signaling events mediated by anti-Ig or TGF-beta1 lead to
an opening of the local chromatin to allow Zta to bind. This
is a reasonable hypothesis however there are two previous
observations suggesting that other more complex possibil-
ities should be considered. Deng et al. (2003) showed that
ectopic Zta can bind to Zp in latently infected cells and
Jenkins et al. (2000) have shown that there is no gross
alteration in nucleosome phasing at Zp following induction.
While there may be trivial explanations for these latter
observations, it is also possible that Zta may be able to bind
Zp during either the latent or the reactivated state but that in
the absence of other signaling events mediated by TGF-
beta1 or anti-Ig, Zta is not capable by itself to overcome
some key imprinted obstacle to transcriptional activation of
endogenous Zp. Regardless of the mechanistic details
involved in this process, the idea that Zta cannot induce
Zp during latency but can induce Zp during reactivation
conditions suggests that EBV has evolved with a mecha-
nism to help suppress spurious entry into the lytic cycle
unless bona fide reactivation signaling is detected (Fig. 7).
In this case, some degree of leakiness of Zp could be
tolerated during latency, but such low levels of spurious Zta
would not lead to commitment to full Zp function through
the autoactivation loop. However, during the appropriate
conditions (e.g., following TGF-beta1 signaling or B cell
receptor engagement), low levels of Zta would be fully
capable of autoactivation and would lead to a commitment
to high level Zta expression and commitment to entry into
the complete lytic cascade.
In anti-Ig-treated Akata cells, there is a significant and
reproducible increase in Zta binding at 2 h post-induction
that coincides with a relatively moderate increase in the level
of Zta observed by Western blot analysis (see Figs. 2 and 3).
This is consistent with previous studies where nuclear
extracts prepared from anti-Ig-treated Akata cells contained
a significant level of Zta DNA binding activity (in vitro) as
early as 1 h post-induction and this binding activity was
approximately equal to the level of Zta DNA binding activity
observed in extracts prepared at 3 h post-induction (Bryant
and Farrell, 2002). These in vitro binding studies were
carried out using one of the Zta binding sites from the Zta
promoter, ZIIIB. These data together with our data indicate
that in anti-Ig-treated Akata cells, Zta that is produced at the
initial stages of induction may be modified (perhaps through
anti-Ig-mediated signaling) in a manner that engenders it
with a high DNA binding affinity (at least to binding sites
within Zp). This idea is consistent with an autoactivation
model because such a model requires that Zta plays a role in
the ramping up of Zta expression and not necessarily after
high levels of Zta have already been produced.
We have also observed that Zdn inhibits the expression
of Rta whose promoter Rp has been shown in reporter
assays to be responsive to Zta. Our studies provide evidence
that indeed, Zta may play an important role in endogenous
Rp function during reactivation. It should also be pointedout that Rp-initiated transcripts can generate a bicistronic
message containing the Zta open reading frame. We
considered the possibility that because Zdn inhibits Zta-
mediated induction of Rp, inhibition of Zta expression by
Zdn may result indirectly through inhibition of Rp.
However, Le Roux et al. (1996) have shown that while
Rta is translated from the bicistronic Rp-initiated message,
Zta is not. This argues that inhibition of Zta expression is
specifically due to a direct effect on Zp-initiated transcripts
from which Zta is efficiently translated.Materials and methods
Cell culture
Akata and Mutu I cells were grown in RPMI 1640 (Life
Technologies) supplemented with 10% fetal bovine serum
(Life Technologies), penicillin, and streptomycin. NPC-KT
and 293 cells were maintained in Dulbecco’s modified
Eagles medium (DMEM, Life Technologies) supplemented
with 10% fetal bovine serum, penicillin, and streptomycin.
All cells were grown at 37 8C in a humidified 5% CO2-
containing atmosphere.
Transfections
Transfections were performed using a modified version
of the calcium phosphate precipitation procedure (detailed
protocol available at www.flemingtonlab.com). Briefly, 2–5
 105 cells were plated onto 100-mm diameter tissue culture
dishes. The following day, the medium was replaced with 8
ml of fresh supplemented DMEM. Four to six hours later,
DNA precipitates were generated by mixing 0.5 ml of 1
HEPES-buffered saline [0.5% HEPES, 0.8% NaCl, 0.1%
dextrose, 0.01% anhydrous Na2HPO4, 0.37% KCl, pH7.10]
with a total of 30 Ag of plasmid DNA followed by the
addition of 30 Al of 2.5 M CaCl2. Precipitates were allowed
to form at room temperature for 20 min before adding
dropwise to cells. Cells were incubated at 37 8C with 5%
CO2 for 16 h before the media were replaced with 10 ml of
fresh DMEM (+10% FBS).
Lytic cycle induction
Mutu I or Akata cells were grown to near saturation and
the day before induction, a 50% volume of fresh RPMI
(+10% FBS, pen/strep) was added. The next day, cells were
spun down and resuspended in an equal volume of fresh-
warmed RPMI (+10% FBS, pen/strep) containing either 10
Ag/ml anti-IgG (Sigma, Cat#I5260), 10 Ag/ml anti-IgM
(Sigma, Cat#I0759), 5 ng/ml TGF-beta1 (R&D Systems,
Cat#100B), or 100 ng/ml TSA (WAKO Bioproducts,
Cat#200-11993). Cells were harvested at appropriate time
points and subjected to either ChIP analysis or Western blot
analysis.
Fig. 7. Proposed model for regulation of Zp by Zta. In the absence of lytic cycle-inducing signals, suppressor factors such as MEF2D, ZIIR, or ZEB play a role
in compacting the local chromatin structure to prevent binding of spuriously expressed Zta or inhibit the activation function of Zta. Induction of the lytic cycle
results in displacement of HDACs and the recruitment of HAT enzymes (co-activators). This leads to initial expression of Zta and opening of the chromatin
structure or function. This model predicts that the relaxed chromatin structure allows for the binding or function of newly expressed Zta and a resulting high
level of Zp activity and commitment to initiation of the lytic cycle.
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293 cells were transfected with 10 Ag of either pMSCV-
puro or pMSCV-puro-Zdn plus 10 Ag each of the
packaging plasmids, pVSV-G and pvPACK-GPdI (pack-
aging vectors were a kind gift of Dr. Brian Schaefer). The
next day, the media were replaced with 10 ml of fresh
DME (+10%FBS, pen/strep). The following day, the media
were taken off and subjected to two sequential centrifuga-
tions to get rid of residual 293 cells. Mutu I cells were
spun down and resuspended in an equal volume of
supplemented DME plus 16 Ag/ml polybrene and 1 ml
was added to each well of a 6-well plate. Viral supernatant
(1 ml) was added to each well and plates were spun for 1
h at 1000  g. The plates were then transferred to a 37 8C,
5% CO2 incubator. Four hours later, cells for like
infections were pooled, centrifuged, and resuspended in
an equal volume of supplemented RPMI. Two days later,
puromycin was added at 1 Ag/ml and cultured for 5 days
before analysis.ChIP analysis
ChIP studies were carried out as described previously
(Wang et al., 2003). A polyclonal anti-Zta antibody (10 Al;
Taylor et al., 1989) was used for each precipitation
reaction. PCR was carried out using the following primers.
Zp: Zpleft 5V-TTGACACCAGCTTATTTTAGACACTTCT
-3V and Zpright 5V-TTACCTGTCTAACATCTCCCCTT-
TAAA-3V [which gives rise to a 181-bp product extending
from 103205 to 103385 of the B95-8 sequence (191 to
11 of Zp)], Z exon 3: Zex3left: 5V-CTGCTGCCAAAT-
CATCTGAA-3V (102318–102337) and Zex3right: 5V-CA
AAGAGAGCCGACAGGAAG-3V (102128–102147), Qp:
Qpleft: 5V-AAATTGGGTGACCACTGAGG-3V (62327–6
2 346) and Qpright (62 522–62 541), and LMPp:
LMP1pleft: 5V-CCGACCCTTAGCCCTCTTAG-3V (169
953–169972) and LMP1pright: 5V-CAAGTGCAACAGG
AAATGGA-3V (169749–169768). PCR reactions were
carried out using iCycler iQ Real-Time Detection System
(Bio-Rad) with Syber Green.
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After a single 1 PBS wash, cells were immediately
suspended in 300 Al sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (SDS-PAGE) loading buffer [125 mM
Tris (pH 6.80), 10% glycerol, 2% SDS, 5% 2-mercaptoe-
thanol, 0.05% bromphenol blue] and boiled for 20 min to
shear the genomic DNA. Whole-cell extracts were measured
with the Bio-Rad protein assay kit according to the
manufacturer’s instructions. Equal weight of cell lysates
were subjected to SDS-PAGE electrophoresis and trans-
ferred to nitrocellulose membranes. The blots were blocked
for 30 min in Tris-buffered saline containing 5% low-fat
powdered milk and 1% fetal bovine serum, and then
incubated with the primary antibody (in blocking buffer)
overnight 4 8C. The blots were washed, incubated with
secondary antibody for 1 h, washed again, and analyzed by
enhanced chemiluminescence.
Plasmid construction
The Zta cDNA fragment encoding amino acids 197–245
of Zta was excised from pCMV-Zta using PstI and EcoRI.
Amino acids 176–196 plus the Zta Met initiation codon were







GAT-3V. The sense and antisense strands of ZdnAdap1 and
ZdnAdap2 were annealed separately and were then added to
a ligation reaction containing the PstI/EcoRI Zta fragment
plus BglII- and EcoRI-digested pMSCV-puro. Positive
clones were verified by sequencing to ensure that there were
no oligonucleotide synthesis errors.Acknowledgments
We thank Zhen Lin and Tara Arrowood for reading the
manuscript and providing suggestions. We are also grateful
to George Miller for providing an anti-Zta antibody. This
work was supported by grant R01 GM48045 (EKF) and a
Tulane Cancer Center Fellowship (QY).References
Adamson, A., Darr, D., Holley-Guthrie, E., Johnson, R., Mauser, A.,
Swenson, J., Kenney, S., 2000. Epstein–Barr virus immediate early
proteins BZLF1 and BRLF1 activate the ATF2 transcription factor by
increasing the levels of phosphorylated p38 and c-Jun N-terminal
kinases. J. Virol. 74, 1224–1233.Baumann, M., Mischak, H., Dammeier, S., Kolch, W., Gires, O., Pich, D.,
Zeidler, R., Delecluse, H.-J., Hammerschmidt, W., 1998. Activation of
the Epstein–Barr virus transcription factor BZLF1 by 12-O-tetrade-
canolyphorbol-13-acetate-induced phosphorylation. J. Virol. 72,
8105–8114.
Borras, A., Strominger, J., Speck, S., 1996. Characterization of the ZI
domain in the Epstein Barr virus BZLF1 gene promoter: role in phorbol
ester induction. J. Virol. 70, 3894–3901.
Bryant, H., Farrell, P., 2002. Signal transduction and transcription factor
modification during reactivation of Epstein–Barr virus from latency.
J. Virol. 76, 10290–10298.
Countryman, J., Jensen, H., Seibel, R., Wolf, H., Miller, G., 1987.
Polymorphic proteins encoded within BZLF1 of defective and standard
Epstein–Barr viruses disrupt latency. J. Virol. 61, 3672–3679.
Deng, Z., Chen, C.-J., Chamberlin, M., Lu, F., Blobel, G., Speicher,
D., Cirillo, L., Zaret, K., Lieberman, P., 2003. The CBP bromodo-
main and nucleosome targeting are required for Zta-directed nuc-
leosome acetylation and transcription activation. Mol. Cell. Biol. 23,
2633–2644.
Flemington, E., Speck, S., 1990a. Autoregulation of the Epstein–Barr virus
putative lytic switch gene BZLF1. J. Virol. 64, 1227–1232.
Flemington, E., Speck, S., 1990b. Identification of phorbol ester response
elements in the promoter of the Epstein–Barr virus putative lytic switch
gene BZLF1. J. Virol. 64, 1217–1226.
Flemington, E.K., Goldfeld, A.E., Speck, S.H., 1991. Efficient transcription
of the Epstein–Barr virus immediate-early BZLF1 and BRLF1 genes
requires protein synthesis. J. Virol. 65, 7073–7077.
Flemington, E., Borras, A.M., Lytle, J.P., Speck, S., 1992. Characterization of
the Epstein–Barr virus BZLF1 protein trans-activation domain. J. Virol.
66, 922–929.
Gruffat, H., Manet, E., Sergeant, A., 2002. MEF2-mediated recruitment of
class II HDAC at the EBV immediate early BZLF1 links latency and
chromatin remodeling. EBMO Rep. 3, 141–146.
Jenkins, P., Binne, U., Farrell, P., 2000. Histone acetylation and reactivation
of Epstein–Barr virus from latency. J. Virol. 74, 710–720.
Kieff, E., Liebowitz, D., 1990. Epstein–Barr virus and its replication. In:
Fields, B.N., Knipe, D.M. (Eds.), Virology. Raven Press, New York,
pp. 1889–1920.
Kolman, J.L., Taylor, N., Gradoville, L., Countryman, J., Miller, G., 1996.
Comparing transcriptional activation and autostimulation by ZEBRA
and ZEBRA/c-Fos chimeras. J. Virol. 70, 1493–1504.
Kraus, R., Mirocha, S., Stephany, H., Puchalski, J., Mertz, J., 2001.
Identification of a novel element involved in regulation of the lytic
switch BZLF1 promoter of Epstein–Barr virus. J. Virol. 75, 867–877.
Kraus, R., Perrigoue, J., Mertz, J., 2003. ZEB negatively regulates the lytic-
switchBZLF1 gene promoter of Epstein–Barr virus. J. Virol. 77, 199–207.
Le Roux, F., Sergeant, A., Corbo, L., 1996. Epstein–Barr virus (EBV) EB1/
Zta protein provided in trans and competent for the activation of
productive cycle genes does not activate the BZLF1 gene in the EBV
genome. J. Gen. Virol. 77, 501–509.
Lieberman, P., Berk, A., 1990. In vitro transcriptional activation, dimeriza-
tion, and DNA-binding specificity of the Epstein–Barr virus Zta protein.
J. Virol. 64, 2560–2568.
Liu, S., Borras, A., Liu, P., Suske, G., Speck, S., 1997. Binding of the
ubiquitous cellular transcription factors Sp1 and Sp3 to the ZI domains
in the Epstein–Barr virus lytic switch BZLF1 gene promoter. Virology
228, 11–18.
Liu, P., Liu, S., Speck, S., 1998. Identification of a negative cis element
within the ZII domain of the Epstein–Barr virus lytic switch BZLF1
gene promoter. J. Virol. 72, 8230–8239.
Miller, G., 1990. Epstein–Barr virus. In: Fields, B.N., Knipe, D.M. (Eds.),
Virology. Raven Press, New York, pp. 1921–1958.
Miller, G., Rabson, M., Heston, L., 1984. Epstein–Barr virus with
heterogeneous DNA disrupts latency. J. Virol. 50, 174–182.
Rodriguez, A., Armstrong, M., Dwyer, D., Flemington, E., 1999. Genetic
dissection of cell growth arrest functions mediated by the Epstein–Barr
virus lytic gene product, Zta. J. Virol. 73, 9029–9038.
Q. Yin et al. / Virology 327 (2004) 134–143 143Rodriguez, A., Jung, E., Yin, Q., Cayrol, C., Flemington, E., 2001. Role of
c-myc regulation in Zta mediated induction of the cyclin dependent
kinase inhibitors, p21 and p27, and cell growth arrest. Virology 284,
159–169.
Ruf, I., Rawlins, D., 1995. Identification and characterization of the ZIIBC,
a complex formed by cellular factors and the ZII site of the Epstein–
Barr virus BZLF1 promoter. J. Virol. 69, 7648–7657.
Speck, S.H., Chatila, T., Flemington, E.K., 1997. Reactivation of Epstein–
Barr virus: regulation and function of the BZLF1 gene. Trends
Microbiol. 5, 399–405.
Takada, K., Ono, Y., 1989. Synchronous and sequential activation of
latently infected Epstein–Barr virus genomes. J. Virol. 63, 445–449.
Taylor, N., Countryman, J., Rooney, C., Katz, D., Miller, G., 1989.
Expression of the BZLF1 latency-disrupting gene differs in standard
and defective Epstein–Barr viruses. J. Virol. 63, 1721–1728.Urier, G., Buisson, M., Chambard, P., Sergeant, A., 1989. The Epstein–Barr
virus early protein EB1 activates transcription from different responsive
elements including AP-1 binding sites. EMBO J. 8, 1447–1453.
Wang, S., Wu, F., Fujimuro, M., Zong, J., Hayward, S., Hayward, G., 2003.
Role of CCAAT/enhancer-binding protein alpha (C/EBPalpha) in
activation of the Kaposi’s sarcoma-associated herpesvirus (KSHV)
lytic-cycle replication-associated protein (RAP) promoter in coopera-
tion with the KSHV replication and transcription activator (RTA) and
RAP. J. Virol. 77, 600–623.
Wu, F., Wang, S., Chen, H., Wang, L., Hayward, S., Hayward, G., 2004.
CCAAT/enhancer binding protein alpha binds to the Epstein–Barr virus
(EBV) Zta protein through oligomeric interactions and contributes to
cooperative transcriptional activation of the Zta promoter through direct
binding to the ZII and ZIIIB motifs during induction of the EBV lytic
cycle. J. Virol. 78, 4847–4865.
